Chronic kidney disease (CKD) is a life-threatening disease that is vastly underdiagnosed and affects an estimated 37 million, or 1 in 7, American adults.[1][2] With limited treatment options available, a new therapy is critical for people living with CKD to help slow disease progression – which is why the recent FDA approval of a new therapy to treat CKD in patients at risk of progression with and without type 2 diabetes (T2D) is monumental for this patient population.
CKD is a progressive condition and patients with CKD have an increased risk of having heart disease.
Chronic kidney disease (CKD) is a life-threatening disease that is vastly underdiagnosed and affects an estimated 37 million, or 1 in 7, American adults.[1][2] With limited treatment options available, a new therapy is critical for people living with CKD to help slow disease progression – which is why the recent FDA approval of a new therapy to treat CKD in patients at risk of progression with and without type 2 diabetes (T2D) is monumental for this patient population.
CKD is a progressive condition and patients with CKD have an increased risk of having heart disease.
for video and more info, go to http://goodnewsplanet.com/the-first-major-development-in-20-years-to-help-manage-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes/
#astrazeneca #farxiga #kidney #disease #health #chronic #patient #risk #diabetes #treatment #therapy #heart #ckd #neil #skolnik #thomas #jefferson #medicine #medical #family #factors
read more
read less
